Edwards Lifesciences (EW) Misses Q2 EPS by 1c, Q3 Revenue Guidance Misses

Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.63, $0.01 worse than the analyst estimate of $0.64. Revenue for the quarter came in at $1.37 billion versus the consensus estimate of $1.4 billion.

GUIDANCE:

Edwards Lifesciences sees Q3 2022 EPS of $0.58-$0.66, versus the consensus of $0.65. Edwards Lifesciences sees Q3 2022 revenue of $1.3-1.37 billion, versus the consensus of $1.44 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Amneal gets FDA approval for lanreotide injection, launches immediately
• Corpay agrees to $100M FTC settlement over marketing practices